PhRASe v1.0

  • Research type

    Research Study

  • Full title

    Prehospital Recognition and Antibiotics for 999 patients with Sepsis (PhRASe): a feasibility study

  • IRAS ID

    213623

  • Contact name

    Chris Moore

  • Contact email

    chris.moore@wales.nhs.uk

  • Sponsor organisation

    Welsh Ambulance Services NHS Trust

  • ISRCTN Number

    ISRCTN36856873

  • Duration of Study in the UK

    1 years, 11 months, 28 days

  • Research summary

    In this study we aim to find out whether paramedics identifying; obtaining blood cultures from; and providing intravenous (IV) antibiotics to, patients with sepsis is feasible, safe and acceptable. This will enable us to make a decision about whether we should proceed to a fully-powered randomised controlled trial that can answer questions about whether the procedure is effective for patients and worthwhile for the NHS. We aim to recruit 60 paramedics out of approximately 100 working in the study area. Recruited paramedics will receive training in recognition of sepsis and the practical procedure of obtaining blood cultures. If sepsis is suspected, paramedics will take the next sequential individually issued scratchcard to randomly allocate the patient to intervention or usual care. We will follow up patients anonymously using routinely collected data and the SAIL (secure anonymised information linkage) databank to see if there are any differences in outcomes between groups, for example mortality rates, length of hospital stay, or time spent with paramedics. We will send patients a questionnaire at approximately 90 days after their 999 call to see if there is any difference in health-related quality of life or satisfaction with the care received from paramedics between the two groups (intervention and control). We will interview ten patients and hold a focus group with paramedics, to find out what they thought about and their experiences of the intervention.

  • REC name

    Wales REC 4

  • REC reference

    17/WA/0186

  • Date of REC Opinion

    4 Jul 2017

  • REC opinion

    Further Information Favourable Opinion